Sarepta Therapeutics
SRPT
344 hedge funds and large institutions have $2.23B invested in Sarepta Therapeutics in 2026 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 110 increasing their positions, 128 reducing their positions, and 48 closing their positions.
11% more capital invested
Capital invested by funds: $2.01B → $2.23B (+$220M)
8.92% more ownership
Funds ownership: 89.12% → 98.04% (+8.9%)
6% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 48
1% less funds holding
Funds holding: 346 → 344 (-2)
3% less call options, than puts
Call options by funds: $102M | Put options by funds: $105M
14% less repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 128
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$75.5M |
| 2 |
Two Sigma Investments
New York
|
+$41.6M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$41.5M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$17.3M |
| 5 |
Morgan Stanley
New York
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$26.4M |
| 2 |
D.E. Shaw & Co
New York
|
-$20.6M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$8.63M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$7.52M |
| 5 |
HF
HRT Financial
New York
|
-$5.69M |
SRPT Hedge Fund Activity: Q1 2026 in Review
344 institutional investors reported a position in Sarepta Therapeutics (SRPT) for Q1 2026, worth a combined $2.23B — up 11% from $2.01B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new SRPT positions and 48 closed out — a net gain of 3 holders — while 110 added to existing stakes and 128 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $75.5M. The largest seller was AQR Capital Management, cutting an estimated $26.4M.
- 344 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2026, down from 346 in Q4 2025.
- Funds reported $2.23B of Sarepta Therapeutics stock for Q1 2026, up 11% quarter-over-quarter.
- 51 funds opened new Sarepta Therapeutics positions in Q1 2026 and 48 closed out, a net change of +3 holders.
- The largest Sarepta Therapeutics buyer in Q1 2026 was RA Capital Management, an estimated $75.5M added.
- The largest Sarepta Therapeutics seller in Q1 2026 was AQR Capital Management, an estimated $26.4M sold.
Based on aggregated 13F filings for Q1 2026.